{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T03:56:43Z","timestamp":1770263803246,"version":"3.49.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,12]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Bevacizumab (Bev) is a humanized monoclonal antibody that targets vascular endothelial growth factor A and is primarily used for the treatment of various solid tumors. Aortic dissection (AD) is a severe vascular disease caused by the tearing of the intimal layer of the aorta or bleeding within the aortic wall, resulting in the separation of different layers of the aortic wall. However, the pathogenesis is not fully understood. Some studies have suggested that Bev treatment is associated with the occurrence of AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 67-year-old Chinese male was diagnosed with rectal cancer accompanied by liver and lung metastasis. Three days after starting combined chemotherapy with Bev, the patient developed persistent abdominal pain. Abdominal CT scan revealed celiac trunk AD in the abdominal aorta.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>The patient was diagnosed with rectal cancer accompanied by liver and lung metastases. Abdominal CT tomography revealed a celiac trunk AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Somatostatin combined with valsartan was used to control blood pressure. The patient was subsequently referred for vascular surgery and underwent an abdominal aortic angiography. Conservative treatment was continued.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Three months after the initiation of treatment, follow-up abdominal CT scans showed stability in the condition of celiac trunk AD, with no abdominal pain or hypertension. There were no signs of worsening dissection, aneurysm formation, or inadequate perfusion of end organs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>There may be a connection between Bev and elevated blood pressure as well as celiac trunk AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000038882","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T15:05:57Z","timestamp":1720796757000},"page":"e38882","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Celiac trunk aortic dissection induced by bevacizumab therapy for rectal cancer: A case report"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9320-4584","authenticated-orcid":false,"given":"Mingming","family":"Su","sequence":"first","affiliation":[{"name":"Department of Medical of Oncology, Affiliated Huishan Hospital of Xinglin College, Nantong University, Wuxi Huishan District People\u2019s Hospital, Wuxi, Jiangsu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Medical of Oncology, Affiliated Huishan Hospital of Xinglin College, Nantong University, Wuxi Huishan District People\u2019s Hospital, Wuxi, Jiangsu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical of Oncology, Affiliated Huishan Hospital of Xinglin College, Nantong University, Wuxi Huishan District People\u2019s Hospital, Wuxi, Jiangsu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical of Oncology, Affiliated Huishan Hospital of Xinglin College, Nantong University, Wuxi Huishan District People\u2019s Hospital, Wuxi, Jiangsu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-2852","authenticated-orcid":false,"given":"Ning","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Medical of Oncology, Affiliated Huishan Hospital of Xinglin College, Nantong University, Wuxi Huishan District People\u2019s Hospital, Wuxi, Jiangsu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260204","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook.","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"R2-20260204","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00228-012-1232-7","article-title":"Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database.","volume":"68","author":"Taugourdeau-Raymond","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R3-20260204","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2017.08.012","article-title":"Bevacizumab-induced hypertension: clinical presentation and molecular understanding.","volume":"182","author":"Li","year":"2018","journal-title":"Pharmacol Ther"},{"key":"R4-20260204","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2146\/ajhp080455","article-title":"Understanding and managing the possible adverse effects associated with bevacizumab.","volume":"66","author":"Shord","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"R5-20260204","first-page":"290","article-title":"Aortic dissection.","volume":"73","author":"Tchana-Sato","year":"2018","journal-title":"Rev Med Liege"},{"key":"R6-20260204","doi-asserted-by":"crossref","first-page":"1545.e3","DOI":"10.1016\/j.ajem.2020.04.041","article-title":"Spontaneous celiac artery dissection.","volume":"38","author":"Hoglund","year":"2020","journal-title":"Am J Emerg Med"},{"key":"R7-20260204","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.avsg.2015.12.009","article-title":"Systematic literature review on evaluation and management of isolated spontaneous celiac trunk dissection.","volume":"34","author":"Cavalcante","year":"2016","journal-title":"Ann Vasc Surg"},{"key":"R8-20260204","first-page":"30","article-title":"Spontaneous celiac artery dissection and its management.","volume":"4","author":"Vaidya","year":"2010","journal-title":"J Radiol Case Rep"},{"key":"R9-20260204","doi-asserted-by":"crossref","first-page":"w14489","DOI":"10.4414\/smw.2017.14489","article-title":"Acute aortic dissection: pathogenesis, risk factors and diagnosis.","volume":"147","author":"Gawinecka","year":"2017","journal-title":"Swiss Med Wkly"},{"key":"R10-20260204","doi-asserted-by":"crossref","first-page":"e006278","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20000 patients.","volume":"6","author":"Totzeck","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"R11-20260204","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1055\/s-0031-1280652","article-title":"Hepatic artery dissection in a patient on bevacizumab resulting in pseudoaneurysm formation.","volume":"28","author":"Brown","year":"2011","journal-title":"Semin Intervent Radiol"},{"key":"R12-20260204","doi-asserted-by":"crossref","first-page":"e230421186875","DOI":"10.2174\/1573403X16666201014142930","article-title":"Aortic dissection: a review of the pathophysiology, management and prospective advances.","volume":"17","author":"Sayed","year":"2021","journal-title":"Curr Cardiol Rev"},{"key":"R13-20260204","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1161\/CIRCULATIONAHA.121.056546","article-title":"Blood pressure, hypertension, and the risk of aortic dissection incidence and mortality: results from the J-SCH study, the UK Biobank study, and a meta-analysis of cohort studies.","volume":"145","author":"Hibino","year":"2022","journal-title":"Circulation"},{"key":"R14-20260204","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jamaoncol.2021.0210","article-title":"Association between antiangiogenic drugs used for cancer treatment and artery dissections or aneurysms.","volume":"7","author":"Guyon","year":"2021","journal-title":"JAMA Oncol"},{"key":"R15-20260204","doi-asserted-by":"crossref","first-page":"1189910","DOI":"10.3389\/fphar.2023.1189910","article-title":"Aortic dissection induced by vascular endothelial growth factor inhibitors.","volume":"14","author":"Dai","year":"2023","journal-title":"Front Pharmacol"},{"key":"R16-20260204","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1161\/CIRCULATIONAHA.116.025144","article-title":"Association between aortic dissection and systemic exposure of vascular endothelial growth factor pathway inhibitors in the Japanese adverse drug event report database.","volume":"135","author":"Oshima","year":"2017","journal-title":"Circulation"},{"key":"R17-20260204","doi-asserted-by":"crossref","first-page":"e020844","DOI":"10.1161\/JAHA.121.020844","article-title":"Aneurysm and artery dissection following the use of vascular endothelial growth factor inhibitor: a real-world analysis using a spontaneous reporting system.","volume":"10","author":"Wang","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"R18-20260204","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2005.10.017","article-title":"Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.","volume":"23","author":"Hurwitz","year":"2005","journal-title":"J Clin Oncol"},{"key":"R19-20260204","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3919\/jjsa.75.652","article-title":"A case of aortic dissection that occurred during administration of bevacizumab for advanced breast cancer.","volume":"75","author":"Yoshimura","year":"2014","journal-title":"J Japan Surg Assoc"},{"key":"R20-20260204","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.radcr.2023.03.055","article-title":"Sudden aortic dissection: a cautionary tale for the unexplained back pain during bevacizumab treatment.","volume":"18","author":"Dong","year":"2023","journal-title":"Radiol Case Rep"},{"key":"R21-20260204","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1752-1947-8-48","article-title":"Rupture of abdominal aortic aneurysm after intravitreal bevacizumab injection: a case report.","volume":"8","author":"Baek","year":"2014","journal-title":"J Med Case Rep"},{"key":"R22-20260204","doi-asserted-by":"crossref","first-page":"101249","DOI":"10.1016\/j.cpcardiol.2022.101249","article-title":"Research progress on the pathogenesis of aortic dissection.","volume":"48","author":"Yin","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"R23-20260204","doi-asserted-by":"crossref","first-page":"910","DOI":"10.7150\/thno.66059","article-title":"Dysregulation of interaction between LOX(high) fibroblast and smooth muscle cells contributes to the pathogenesis of aortic dissection.","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"R24-20260204","first-page":"337","article-title":"Recent advances of phenotypic switch of vascular smooth muscle cells in vascular diseases.","volume":"35","author":"Wen","year":"2023","journal-title":"Chin Heart J"},{"key":"R25-20260204","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1536\/ihj.17-461","article-title":"Aortic dissection and cardiac dysfunction emerged coincidentally during the long-term treatment with angiogenesis inhibitors for metastatic renal cell carcinoma.","volume":"59","author":"Takada","year":"2018","journal-title":"Int Heart J"},{"key":"R26-20260204","doi-asserted-by":"crossref","first-page":"e94205","DOI":"10.1371\/journal.pone.0094205","article-title":"Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization.","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"R27-20260204","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41419-020-03161-x","article-title":"Tumor necrosis factor \u03b1 inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer.","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis"},{"key":"R28-20260204","doi-asserted-by":"crossref","first-page":"e00707","DOI":"10.1002\/prp2.707","article-title":"Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection-a pharmacovigilance analysis.","volume":"9","author":"D\u00f6rks","year":"2021","journal-title":"Pharmacol Res Perspect"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038882","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T14:00:22Z","timestamp":1770213622000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":28,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038882","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]}}}